文献速递血液净化与透析

生物阻抗谱加入液体管理方案未改善新入透析患者残余肾功能保留

Bio-impedance spectroscopy added to a fluid management protocol does not improve preservation of residual kidney function in incident hemodialysis patients in a randomized controlled trial.
PubMed 文献 · Kidney Int · 2023-05-30

这项在英國34个中心开展的开放标签随机对照试验纳入439例尿量>500 ml/天或残余GFR>3 ml/min/1.73m²的新入血液透析患者,1:1随机分组,干预组在设定透析后目标体重时参考生物阻抗测得的估计正常水合体重(BI-NHW),对照组对此盲法。主要终点为无尿时间,两组无尿病因别风险率无显著差异(0.751,95%CI 0.459–1.229),残余肾功能下降速度、血压和患者报告结局均无组间差异。

要点

  • 在设定透析后目标体重时使用标准化临床液体评估方案,与残余肾功能保留良好相关。
  • 干预组参考BI-NHW与对照组相比,无尿病因别风险率无显著差异(0.751,95%CI 0.459–1.229)。
  • 残余肾功能下降速度、血压及患者报告结局均无组间差异,生物阻抗测量并非实现该保留所必需。

核心结论

  • 在设定透析后目标体重时使用标准化临床液体评估方案与残余肾功能良好保留相关,生物阻抗测量并非实现这一保留所必需。

研究设计与样本

  • 开放标签随机对照试验,在英国34个中心纳入439例尿量>500 ml/天或残余GFR>3 ml/min/1.73m²的新入血液透析患者,1:1随机分组并按中心分层,临床医生和患者对对照组的生物阻抗读数盲法。
  • 两组均使用标准化表单进行长达24个月的液体评估,干预组额外可获得BI-NHW。
  • 主要终点为无尿时间,采用竞争风险生存模型校正基线特征后按意向性治疗分析。

主要发现

  • 无尿病因别风险率无组间差异(0.751,95%CI 0.459–1.229),子分布风险率亦无组间差异(0.742,95%CI 0.453–1.215)。
  • 残余肾功能下降速度明显慢于预期,汇总线性率第1年为-0.178(95%CI -0.196至-0.159)ml/min/1.73m²/月,第2年为-0.061(95%CI -0.086至-0.036)ml/min/1.73m²/月。
  • 血压和患者报告结局无组间差异。
  • 目标体重与BI-NHW的平均差异一致性两组相似:生物阻抗组-0.04 kg,对照组-0.25 kg。

临床怎么用

  • 作者认为,在设定透析后目标体重时使用标准化临床液体评估方案与残余肾功能良好保留相关,因此生物阻抗测量并非实现这一保留所必需。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Avoiding excessive dialysis-associated volume depletion may help preserve residual kidney function (RKF). To establish whether knowledge of the estimated normally hydrated weight from bioimpedance measurements (BI-NHW) when setting the post-hemodialysis target weight (TW) might mitigate rate of loss of RKF, we undertook an open label, randomized controlled trial in incident patients receiving HD, with clinicians and patients blinded to bioimpedance readings in controls. A total of 439 patients with over 500 ml urine/day or residual GFR exceeding 3 ml/min/1.73m2 were recruited from 34 United Kingdom centers and randomized 1:1, stratified by center. Fluid assessments were made for up to 24 months using a standardized proforma in both groups, supplemented by availability of BI-NHW in the intervention group. Primary outcome was time to anuria, analyzed using competing-risk survival models adjusted for baseline characteristics, by intention to treat. Secondary outcomes included rate of RKF decline (mean urea and creatinine clearance), blood pressure and patient-reported outcomes. There were no group differences in cause-specific hazard rates of anuria (0.751; 95% confidence interval (0.459, 1.229)) or sub-distribution hazard rates (0.742 (0.453, 1.215)). RKF decline was markedly slower than anticipated, pooled linear rates in year 1: -0.178 (-0.196, -0.159)), year 2: -0.061 (-0.086, -0.036)) ml/min/1.73m2/month. Blood pressure and patient-reported outcomes did not differ by group. The mean difference agreement between TW and BI-NHW was similar for both groups, Bioimpedance: -0.04 kg; Control: -0.25 kg. Thus, use of a standardized clinical protocol for fluid assessment when setting TW is associated with excellent preservation of RKF. Hence, bioimpedance measurements are not necessary to achieve this.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Davies SJ, Coyle D, Lindley EJ, et al. Bio-impedance spectroscopy added to a fluid management protocol does not improve preservation of residual kidney function in incident hemodialysis patients in a randomized controlled trial. Kidney Int. 2023. PMID: 37263353. doi:10.1016/j.kint.2023.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。